This invention relates to methods for evaluating the efficacy of an IGF1R inhibitor, such as an anti-IGF1R antibody, for the treatment of an Ewing's sarcoma tumor by determining the level of tumoral glucose metabolism. Tumoral glucose metabolism is determining at an early point in the treatment regimen by any of several methods known in the art including FDG-PET/CT scan.
Sequential Administration Of Chemotherapeutic Agents For Treatment Of Cancer
Yaolin Wang - Edison NJ, US Yan Wang - Warren NJ, US Brian Der-Hua Lu - Westfield NJ, US Ming Liu - Fanwood NJ, US
International Classification:
A61K 39/395 A61P 35/00 A61P 35/02
US Classification:
4241311, 4241301, 4241411, 4241331, 4241361
Abstract:
The present invention relates to the sequential administration of a cytotoxic agent followed by an IGF1R antagonist (e.g., an antibody) for the treatment of hyperproliferative disorders including cancer.
Medicine Doctors
Dr. Brian D Lu, Westfield NJ - MD (Doctor of Medicine)
Nicola Laughlin (1991-1993), Brian Lu (1999-2004), Robert Beltran (1997-2001), Sophia Seto (2001-2005), Lawrence Im (1993-1997), Brent Wessberg (2003-2004)